

## Minutes: Steering Board meeting, 30 October 2020

### 1. COVAX

In a separate meeting, dedicated to COVAX, the European Commission provided a general state of play of the COVAX Facility, stating that the initiative is a success in terms of participation with 184 participants so far, including the 27 EU MS, Norway and Iceland as part of Team Europe. More than a [REDACTED] have been committed to the self-financing side and [REDACTED] in pledges and donations to the AMC part.

The Commission informed that a first meeting of the **Shareholders Council** would take [REDACTED]

- [REDACTED]

[REDACTED] asked the Commission to provide reporting from the Friends of COVAX meeting to those MSs that are not part of the group. Furthermore, [REDACTED] enquired about the process [REDACTED]

The question on how COVAX would manage [REDACTED] was discussed.

### **Liability** [REDACTED]

Member States [REDACTED]

On **financing**, [REDACTED]

The Commission welcomed the bilateral contribution made by some MSs and encouraged all 27 MSs to provide funding bilaterally. [REDACTED]

**Update on Johnson & Johnson contract and** [REDACTED]

The Members were informed that:

- [REDACTED]
- [REDACTED]

**Update on other contracts in the** [REDACTED] **/ discussions with other companies**

**BioNTech**- work on the contract was ongoing, with technical meetings [REDACTED]

Elements of logistics [REDACTED]

[REDACTED]. The Members agreed that the [REDACTED] should be started in advance.

**Curevac** –A third scientific presentation/discussion would be organised on the 3 November. [REDACTED]

**Moderna** –work on the contact is ongoing. Some elements of agreement during negotiations still need to be included in the contract.

**Novavax**- discussions with the company continue. The Members were informed on discussions on liability and indemnification.

**Valneva** - there are [REDACTED] on indemnification and liability, [REDACTED] on the structure of the contract, on price, delivery and payment schedules and options.

[REDACTED] – discussions with the company having concluded, [REDACTED]

The Members were reminded to follow up on their commitment [REDACTED] enable the signature of APAs with vaccine providers/manufacturers.

The Members discussed various aspects on the logistic, which can be relevant in a strategic discussion on the [REDACTED] vaccines.

The Members were informed that at the next meeting AstraZeneca would provide an update on Clinical trials, manufacturing and approval.

The Commission provided a short update on the state of play regarding the **Joint procurement for the supply of medical equipment for COVID-19 vaccination**, for which the evaluation of the tender evaluation was ongoing.

The Commission anticipates the evaluation to be finalized by [REDACTED] (largely depending on the quality of offers and reactivity of companies), while the orders could be placed as of [REDACTED] ensuring that supplies are available in time for national deployment of COVID-19 vaccines.

The Commission also asked the MSs to inform if they launched or signed national procurement on syringes and needles in parallel, information that could be relevant for adjusting the offer to the needs of the Member States. *Note post meeting: The update should be send to: SANTE-LUX-JOINT-PROCUREMENT-SECRETARIAT@ec.europa.eu*

The Committee informed that the Joint Procurement Steering Committee would meet [REDACTED] and update on the joint procurement of syringes and needles.